Clinical Trials Sponsored by Merck Sharp & Dohme Corp

Total 3975 results

Merck Sharp & Dohme LLC

Completed

A Local Experiential Study With Sitagliptin (an Antihyperglycemic Drug) in 30 Patients With Type 2 Diabetes Mellitus (0431-178)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143)

Carcinoma, Non-Small-Cell Lung | Brain Neoplasms | Metastases, Neoplasm
Merck Sharp & Dohme LLC

Completed

Comparison of 4.0 mg/kg Sugammadex at 1-2 Post Tetanic Counts (PTC) in Renal or Control Patients (19.4.328)(P05769)

Anesthesia
Merck Sharp & Dohme LLC

Completed

ALPHA Sitagliptin Add on to Metformin (0431-103)

Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594)

Neoplasms | Nausea | Vomiting
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)

Diabetes Mellitus, Type 2 | Renal Insufficiency, Chronic
Merck Sharp & Dohme LLC

Completed

A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)

Diabetes Mellitus, Type 2 | End-Stage Kidney Disease
Merck Sharp & Dohme LLC

Completed

Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)

Type 2 Diabetes Mellitus (T2DM)
Merck Sharp & Dohme LLC

Completed

Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED)

Spondylitis, Ankylosing
Merck Sharp & Dohme LLC

Completed

Residual Curarization and Its Incidence at Tracheal Extubation (P08194) (RECITE)

Observation of Neuromuscular Block
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122)

Colorectal Adenoma
Merck Sharp & Dohme LLC

Completed

Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247)

Carcinoma, Non-Small-Cell Lung | Neoplasm Metastasis | Brain Neoplasms
Merck Sharp & Dohme LLC

Completed

A Study of Two Approved Drugs in the Treatment of Post-Bunionectomy Surgery Pain (0966-234)(COMPLETED)

Postoperative Pain
Merck Sharp & Dohme LLC

Completed

An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)

Breast Neoplasms | Nausea | Vomiting
Merck Sharp & Dohme LLC

Completed

Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)

Major Depressive Disorder
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)

Major Depressive Disorder
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)

Major Depressive Disorder
Merck Sharp & Dohme LLC

Completed

Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)

Breast Neoplasms | Nausea | Vomiting
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)

Major Depressive Disorder
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)

Major Depressive Disorder
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

GARDASIL Reexamination Study (V501-059)

Human Papillomavirus (HPV) Infection
Merck Sharp & Dohme LLC

Completed

ROTATEQ Reexamination Study (V260-037)

Gastroenteritis Rotavirus
Merck Sharp & Dohme LLC

Completed

Phase III Placebo-controlled Study of V260 (RotaTeq™) in Japanese Healthy Infants (V260-029)(COMPLETED)

Gastroenteritis | Rotavirus
Merck Sharp & Dohme LLC

Completed

Post Approval Pharmacokinetic Study of Loratadine in Japanese Pediatric and Adult Patients (Study P05539)

Perennial Allergic Rhinitis
Merck Sharp & Dohme LLC

Terminated

Treatment With Infliximab in a Medical Setting (Study P05587) (OPTIMIST)

Crohn's Disease
Merck Sharp & Dohme LLC

Completed

Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068)

Hepatitis A Virus
Merck Sharp & Dohme LLC

Terminated

A Study of ProQuad™ in Healthy Children in Korea (V221-023)

Measles | Rubella | Mumps | Varicella
Merck Sharp & Dohme LLC

Completed

Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed)

Varicella
Merck Sharp & Dohme LLC

Terminated

Efficacy & Safety of Infliximab Monotherapy Vs Combination Therapy Vs AZA Monotherapy in Ulcerative Colitis (Part 1) Maintenance Vs Intermittent Therapy for Maintaining Remission (Part 2)(Study P04807)

Ulcerative Colitis
Merck Sharp & Dohme LLC

Completed

Hepatitis B Vaccine Booster Study (V232-058)(COMPLETED)

Hepatitis B
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)

Shingles
Merck Sharp & Dohme LLC

Completed

POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED)

Coccidioidomycosis
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)

Liver Cirrhosis | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Peginterferon Alfa-2b in Participants With Moderate and Severe Renal Impairment (P05655)

Renal Insufficiency
Merck Sharp & Dohme LLC

Terminated

Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)

Hepatitis C, Chronic | Insulin Resistance
Merck Sharp & Dohme LLC

Completed

PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)

Hepatitis B, Chronic
Merck Sharp & Dohme LLC

Completed

Lipid Efficacy Study (0524B-022)(COMPLETED)

Primary Hypercholesterolemia | Mixed Hyperlipidemia
Merck Sharp & Dohme LLC

Completed

Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)

Carcinoma, Hepatocellular
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED) (SPRINT-2)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Terminated

Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)

Liver Transplantation | Liver Cirrhosis | Hepatitis C, Chronic

3

Subscribe